<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Mustang Bio, Inc. — News on 6ix</title>
    <link>https://6ix.com/company/mustang-bio-inc</link>
    <description>Latest news and press releases for Mustang Bio, Inc. on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Mon, 07 Jul 2025 12:30:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/mustang-bio-inc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683595fd78dffbe2df10461a.webp</url>
      <title>Mustang Bio, Inc.</title>
      <link>https://6ix.com/company/mustang-bio-inc</link>
    </image>
    <item>
      <title>Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-101 (IL13Ra2-targeted CAR T-cells) to Treat Astrocytomas and Glioblastoma</title>
      <link>https://6ix.com/company/mustang-bio-inc/news/mustang-bio-granted-orphan-drug-123000232</link>
      <guid isPermaLink="true">https://6ix.com/company/mustang-bio-inc/news/mustang-bio-granted-orphan-drug-123000232</guid>
      <pubDate>Mon, 07 Jul 2025 12:30:00 GMT</pubDate>
      <description>In an ongoing Phase 1 trial published in Nature Medicine, MB-101 was well-tolerated and 50% of patients achieved stable disease or better with two partial responses and two complete responses lasting 7.5 and 66+ months, respectively Preclinical data support a novel combination of MB-101 (IL13Rα2‐targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus) to optimize clinical results FDA previously granted Orphan Drug Designation to Mustang for MB-108 for the treatment of malignant glioma WOR</description>
    </item>
    <item>
      <title>Mustang Bio Regains Compliance with Nasdaq Capital Market Requirement</title>
      <link>https://6ix.com/company/mustang-bio-inc/news/mustang-bio-regains-compliance-nasdaq-211500567</link>
      <guid isPermaLink="true">https://6ix.com/company/mustang-bio-inc/news/mustang-bio-regains-compliance-nasdaq-211500567</guid>
      <pubDate>Wed, 05 Mar 2025 21:15:00 GMT</pubDate>
      <description>WALTHAM, Mass., March 05, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO) today announced that it has received notice from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it has regained compliance with the Nasdaq Capital Market’s minimum stockholders’ equity requirement as required by Nasdaq Listing Rule 5550(b)(1). On February 26, 2025, Mustang received formal notice from Nasdaq confirming that the Company has satisfied the minimum stock</description>
    </item>
    <item>
      <title>Mustang Bio Announces Sale of Fixed Assets and Exit of Facility</title>
      <link>https://6ix.com/company/mustang-bio-inc/news/mustang-bio-announces-sale-fixed-210500538</link>
      <guid isPermaLink="true">https://6ix.com/company/mustang-bio-inc/news/mustang-bio-announces-sale-fixed-210500538</guid>
      <pubDate>Thu, 27 Feb 2025 21:05:00 GMT</pubDate>
      <description>WALTHAM, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell therapies into potential cures for difficult-to-treat cancers, today announced the exit of the lease for its manufacturing facility in Worcester, Massachusetts and concurrent divestment of certain fixed assets including furniture and equipment to AbbVie Bioresearch Center Inc., a De</description>
    </item>
    <item>
      <title>Mustang Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement</title>
      <link>https://6ix.com/company/mustang-bio-inc/news/mustang-bio-regains-compliance-with-nasdaq-minimum-bid-price-requirement-1</link>
      <guid isPermaLink="true">https://6ix.com/company/mustang-bio-inc/news/mustang-bio-regains-compliance-with-nasdaq-minimum-bid-price-requirement-1</guid>
      <pubDate>Tue, 11 Feb 2025 05:00:00 GMT</pubDate>
      <description>WORCESTER, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO) today announced that it has received notice</description>
    </item>
    <item>
      <title>Mustang Bio Announces Closing of $8 Million Public Offering</title>
      <link>https://6ix.com/company/mustang-bio-inc/news/mustang-bio-announces-closing-of-dollar8-million-public-offering</link>
      <guid isPermaLink="true">https://6ix.com/company/mustang-bio-inc/news/mustang-bio-announces-closing-of-dollar8-million-public-offering</guid>
      <pubDate>Mon, 10 Feb 2025 05:00:00 GMT</pubDate>
      <description>WORCESTER, Mass., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company</description>
    </item>
    <item>
      <title>Mustang Bio Announces Pricing of $8 Million Public Offering</title>
      <link>https://6ix.com/company/mustang-bio-inc/news/mustang-bio-announces-pricing-of-dollar8-million-public-offering</link>
      <guid isPermaLink="true">https://6ix.com/company/mustang-bio-inc/news/mustang-bio-announces-pricing-of-dollar8-million-public-offering</guid>
      <pubDate>Thu, 06 Feb 2025 05:00:00 GMT</pubDate>
      <description>WORCESTER, Mass., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company</description>
    </item>
    <item>
      <title>Mustang Bio Announces Reverse Stock Split</title>
      <link>https://6ix.com/company/mustang-bio-inc/news/mustang-bio-announces-reverse-stock-split</link>
      <guid isPermaLink="true">https://6ix.com/company/mustang-bio-inc/news/mustang-bio-announces-reverse-stock-split</guid>
      <pubDate>Tue, 14 Jan 2025 05:00:00 GMT</pubDate>
      <description>WORCESTER, Mass., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company</description>
    </item>
    <item>
      <title>Mustang Bio Receives Positive Listing Determination from Nasdaq</title>
      <link>https://6ix.com/company/mustang-bio-inc/news/mustang-bio-receives-positive-listing-determination-from-nasdaq</link>
      <guid isPermaLink="true">https://6ix.com/company/mustang-bio-inc/news/mustang-bio-receives-positive-listing-determination-from-nasdaq</guid>
      <pubDate>Tue, 12 Nov 2024 05:00:00 GMT</pubDate>
      <description>WORCESTER, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company</description>
    </item>
    <item>
      <title>Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-108 (HSV-1 oncolytic virus) to Treat Malignant Glioma</title>
      <link>https://6ix.com/company/mustang-bio-inc/news/mustang-bio-granted-orphan-drug-designation-by-us-fda-for-mb-108-hsv-1-oncolytic-virus-to-treat-malignant-glioma</link>
      <guid isPermaLink="true">https://6ix.com/company/mustang-bio-inc/news/mustang-bio-granted-orphan-drug-designation-by-us-fda-for-mb-108-hsv-1-oncolytic-virus-to-treat-malignant-glioma</guid>
      <pubDate>Thu, 07 Nov 2024 05:00:00 GMT</pubDate>
      <description>MB-108 (HSV-1 oncolytic virus) is active and well tolerated in patients with recurrent glioblastoma in ongoing Phase 1 clinical trial Preclinical data support</description>
    </item>
    <item>
      <title>Mustang Bio Announces Exercise of Warrants for $4 Million Gross Proceeds</title>
      <link>https://6ix.com/company/mustang-bio-inc/news/mustang-bio-announces-exercise-of-warrants-for-dollar4-million-gross-proceeds</link>
      <guid isPermaLink="true">https://6ix.com/company/mustang-bio-inc/news/mustang-bio-announces-exercise-of-warrants-for-dollar4-million-gross-proceeds</guid>
      <pubDate>Thu, 24 Oct 2024 04:00:00 GMT</pubDate>
      <description>WORCESTER, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company</description>
    </item>
    <item>
      <title>Mustang Bio Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules</title>
      <link>https://6ix.com/company/mustang-bio-inc/news/mustang-bio-announces-dollar25-million-registered-direct-offering-priced-at-the-market-under-nasdaq-rules</link>
      <guid isPermaLink="true">https://6ix.com/company/mustang-bio-inc/news/mustang-bio-announces-dollar25-million-registered-direct-offering-priced-at-the-market-under-nasdaq-rules</guid>
      <pubDate>Thu, 20 Jun 2024 04:00:00 GMT</pubDate>
      <description>WORCESTER, Mass., June 20, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company</description>
    </item>
    <item>
      <title>Mustang Bio Announces Favorable Efficacy and Safety Data from Complete Waldenstrom Macroglobulinemia Cohort of Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR-T Therapy</title>
      <link>https://6ix.com/company/mustang-bio-inc/news/mustang-bio-announces-favorable-efficacy-and-safety-data-from-complete-waldenstrom-macroglobulinemia-cohort-of-phase-12-clinical-trial-of-mb-106-cd20-targeted-autologous-car-t-therapy</link>
      <guid isPermaLink="true">https://6ix.com/company/mustang-bio-inc/news/mustang-bio-announces-favorable-efficacy-and-safety-data-from-complete-waldenstrom-macroglobulinemia-cohort-of-phase-12-clinical-trial-of-mb-106-cd20-targeted-autologous-car-t-therapy</guid>
      <pubDate>Mon, 17 Jun 2024 04:00:00 GMT</pubDate>
      <description>Overall response rate of 90% in cohort with durable responses observed; one patient remains in complete remission at 31 months All patients were heavily</description>
    </item>
    <item>
      <title>Mustang Bio Announces Closing of $4 Million Public Offering</title>
      <link>https://6ix.com/company/mustang-bio-inc/news/mustang-bio-announces-closing-of-dollar4-million-public-offering</link>
      <guid isPermaLink="true">https://6ix.com/company/mustang-bio-inc/news/mustang-bio-announces-closing-of-dollar4-million-public-offering</guid>
      <pubDate>Thu, 02 May 2024 04:00:00 GMT</pubDate>
      <description>Potential Additional Gross Proceeds Upon Cash Exercise of Warrants of Up to $12 Million WORCESTER, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc.</description>
    </item>
    <item>
      <title>Mustang Bio Announces Pricing of $4 Million Public Offering</title>
      <link>https://6ix.com/company/mustang-bio-inc/news/mustang-bio-announces-pricing-of-dollar4-million-public-offering</link>
      <guid isPermaLink="true">https://6ix.com/company/mustang-bio-inc/news/mustang-bio-announces-pricing-of-dollar4-million-public-offering</guid>
      <pubDate>Mon, 29 Apr 2024 04:00:00 GMT</pubDate>
      <description>WORCESTER, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company</description>
    </item>
    <item>
      <title>Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases</title>
      <link>https://6ix.com/company/mustang-bio-inc/news/mustang-bio-announces-vision-for-car-t-cell-therapy-platform-expansion-into-autoimmune-diseases</link>
      <guid isPermaLink="true">https://6ix.com/company/mustang-bio-inc/news/mustang-bio-announces-vision-for-car-t-cell-therapy-platform-expansion-into-autoimmune-diseases</guid>
      <pubDate>Thu, 28 Mar 2024 04:00:00 GMT</pubDate>
      <description>Planning for proof-of concept Phase 1 investigator-sponsored clinical trial evaluating MB-106 CD20-targeted CAR T-cell therapy in autoimmune diseases is</description>
    </item>
    <item>
      <title>Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate Highlights</title>
      <link>https://6ix.com/company/mustang-bio-inc/news/mustang-bio-reports-full-year-2023-financial-results-and-recent-corporate-highlights</link>
      <guid isPermaLink="true">https://6ix.com/company/mustang-bio-inc/news/mustang-bio-reports-full-year-2023-financial-results-and-recent-corporate-highlights</guid>
      <pubDate>Mon, 11 Mar 2024 04:00:00 GMT</pubDate>
      <description>WORCESTER, Mass., March 11, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company</description>
    </item>
    <item>
      <title>Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Glioma</title>
      <link>https://6ix.com/company/mustang-bio-inc/news/mustang-bio-announces-publication-in-nature-medicine-of-data-from-phase-1-trial-evaluating-mb-101-il13ra2-targeted-car-t-cells-in-high-grade-glioma</link>
      <guid isPermaLink="true">https://6ix.com/company/mustang-bio-inc/news/mustang-bio-announces-publication-in-nature-medicine-of-data-from-phase-1-trial-evaluating-mb-101-il13ra2-targeted-car-t-cells-in-high-grade-glioma</guid>
      <pubDate>Thu, 07 Mar 2024 05:00:00 GMT</pubDate>
      <description>MB-101 was well-tolerated and 50% of patients achieved stable disease or better with two partial responses and two complete responses lasting 7.5 and 66+</description>
    </item>
    <item>
      <title>Mustang Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference</title>
      <link>https://6ix.com/company/mustang-bio-inc/news/mustang-bio-to-participate-in-the-b-riley-securities-4th-annual-oncology-conference</link>
      <guid isPermaLink="true">https://6ix.com/company/mustang-bio-inc/news/mustang-bio-to-participate-in-the-b-riley-securities-4th-annual-oncology-conference</guid>
      <pubDate>Thu, 11 Jan 2024 05:00:00 GMT</pubDate>
      <description>WORCESTER, Mass., Jan. 11, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company</description>
    </item>
    <item>
      <title>Mustang Bio Presents Updated Phase 1/2 Multicenter Clinical Data for MB-106 at the 2023 American Society of Hematology (ASH) Annual Meeting</title>
      <link>https://6ix.com/company/mustang-bio-inc/news/mustang-bio-presents-updated-phase-12-multicenter-clinical-data-for-mb-106-at-the-2023-american-society-of-hematology-ash-annual-meeting</link>
      <guid isPermaLink="true">https://6ix.com/company/mustang-bio-inc/news/mustang-bio-presents-updated-phase-12-multicenter-clinical-data-for-mb-106-at-the-2023-american-society-of-hematology-ash-annual-meeting</guid>
      <pubDate>Mon, 11 Dec 2023 05:00:00 GMT</pubDate>
      <description>Data showed favorable safety profile, complete response rate and durability in the treatment of patients with relapsed or refractory indolent B-cell</description>
    </item>
    <item>
      <title>Mustang Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights</title>
      <link>https://6ix.com/company/mustang-bio-inc/news/mustang-bio-reports-third-quarter-2023-financial-results-and-recent-corporate-highlights</link>
      <guid isPermaLink="true">https://6ix.com/company/mustang-bio-inc/news/mustang-bio-reports-third-quarter-2023-financial-results-and-recent-corporate-highlights</guid>
      <pubDate>Tue, 14 Nov 2023 05:00:00 GMT</pubDate>
      <description>WORCESTER, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on</description>
    </item>
  </channel>
</rss>